Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients.
The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. In clinical trials, leading candidate CR845 has shown a reduction in pain intensity in patients. The drug has also shown alleviation of moderate-to-severe pruritus associated with chronic kidney disease.
Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29. Cara Therapeutics makes up ~0.10% of the iShares Micro-Cap ETF (IWC).
In January 2018, of the four analysts covering Aquinox Pharmaceuticals (AQXP), two recommended “buy,” and two recommended “strong buy.” The stock had a mean rating of 1.5 and target price of $24.25. Of the nine analysts covering Flexion Therapeutics (FLXN), six analysts recommended “buy” and three recommended “strong buy.” The stock’s mean rating was 1.7 and its target price was $38.44. Of the 13 analysts covering Neurocrine Biosciences (NBIX), eight analysts recommended “buy” and five recommended “strong buy.” The stock had a mean rating of 1.6 and target price of $96. In the next part of this series, we’ll look at Cara Therapeutics’ drugs in development.